Literature DB >> 19568781

Measuring and interpreting the selectivity of protein kinase inhibitors.

Lynette A Smyth1, Ian Collins.   

Abstract

Protein kinase inhibitors are a well-established class of clinically useful drugs, particularly for the treatment of cancer. Achieving inhibitor selectivity for particular protein kinases often remains a significant challenge in the development of new small molecules as drugs or as tools for chemical biology research. This review summarises the methodologies available for measuring kinase inhibitor selectivity, both in vitro and in cells. The interpretation of kinase inhibitor selectivity data is discussed, particularly with reference to the structural biology of the protein targets. Measurement and prediction of kinase inhibitor selectivity will be important for the development of new multi-targeted kinase inhibitors.

Entities:  

Year:  2009        PMID: 19568781      PMCID: PMC2725273          DOI: 10.1007/s12154-009-0023-9

Source DB:  PubMed          Journal:  J Chem Biol        ISSN: 1864-6158


  141 in total

Review 1.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

2.  CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads.

Authors:  Georgette Castanedo; Kevin Clark; Shumei Wang; Vickie Tsui; Mengling Wong; John Nicholas; Dineli Wickramasinghe; James C Marsters; Daniel Sutherlin
Journal:  Bioorg Med Chem Lett       Date:  2005-12-27       Impact factor: 2.823

Review 3.  A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies.

Authors:  Lynn R Zieske
Journal:  J Exp Bot       Date:  2006-03-30       Impact factor: 6.992

Review 4.  Insights for the development of specific kinase inhibitors by targeted structural genomics.

Authors:  Oleg Fedorov; Michael Sundström; Brian Marsden; Stefan Knapp
Journal:  Drug Discov Today       Date:  2007-03-29       Impact factor: 7.851

5.  Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

6.  Reading dynamic kinase activity in living cells for high-throughput screening.

Authors:  Michael D Allen; Lisa M DiPilato; Meghdad Rahdar; Yunzhao R Ren; Curtis Chong; Jun O Liu; Jin Zhang
Journal:  ACS Chem Biol       Date:  2006-07-21       Impact factor: 5.100

7.  The selectivity of inhibitors of protein kinase CK2: an update.

Authors:  Mario A Pagano; Jenny Bain; Zygmunt Kazimierczuk; Stefania Sarno; Maria Ruzzene; Giovanni Di Maira; Matthew Elliott; Andrzej Orzeszko; Giorgio Cozza; Flavio Meggio; Lorenzo A Pinna
Journal:  Biochem J       Date:  2008-11-01       Impact factor: 3.857

8.  Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.

Authors:  Ronald J Hill; Karim Dabbagh; Deborah Phippard; Ching Li; Rebecca T Suttmann; Mary Welch; Eva Papp; Kyung W Song; Kung-Ching Chang; David Leaffer; Yong-Nam Kim; Richard T Roberts; Tanja S Zabka; Dee Aud; Joseph Dal Porto; Anthony M Manning; Stanford L Peng; David M Goldstein; Brian R Wong
Journal:  J Pharmacol Exp Ther       Date:  2008-09-05       Impact factor: 4.030

Review 9.  KIT mutations in GIST.

Authors:  Jonathan A Fletcher; Brian P Rubin
Journal:  Curr Opin Genet Dev       Date:  2007-01-08       Impact factor: 5.578

10.  Prediction of specificity-determining residues for small-molecule kinase inhibitors.

Authors:  Daniel R Caffrey; Elizabeth A Lunney; Deborah J Moshinsky
Journal:  BMC Bioinformatics       Date:  2008-11-25       Impact factor: 3.169

View more
  47 in total

1.  A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.

Authors:  Kristine K Deibler; Rama K Mishra; Matthew R Clutter; Aleksandar Antanasijevic; Raymond Bergan; Michael Caffrey; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

Review 2.  Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.

Authors:  Emilie Patras de Campaigno; Emmanuelle Bondon-Guitton; Guy Laurent; Francois Montastruc; Jean-Louis Montastruc; Maryse Lapeyre-Mestre; Fabien Despas
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

3.  Application of a peptide-based assay to characterize inhibitors targeting protein kinases from yeast.

Authors:  Jenny Veide Vilg; Sita Dahal; Thomas Ljungdahl; Morten Grøtli; Markus J Tamás
Journal:  Curr Genet       Date:  2014-03-19       Impact factor: 3.886

4.  Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors.

Authors:  Yong Xu; Benjamin G Brenning; Steven G Kultgen; Jason M Foulks; Adrianne Clifford; Shuping Lai; Ashley Chan; Shannon Merx; Michael V McCullar; Steven B Kanner; Koc-Kan Ho
Journal:  ACS Med Chem Lett       Date:  2014-10-22       Impact factor: 4.345

Review 5.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

6.  Gini Coefficients as a Single Value Metric to Define Chemical Probe Selectivity.

Authors:  Andrei Ursu; Jessica L Childs-Disney; Alicia J Angelbello; Matthew G Costales; Samantha M Meyer; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2020-07-09       Impact factor: 5.100

7.  Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.

Authors:  Yoshitaka Hiruma; Andre Koch; Nazila Hazraty; Foteini Tsakou; René H Medema; Robbie P Joosten; Anastassis Perrakis
Journal:  J Biol Chem       Date:  2017-07-18       Impact factor: 5.157

Review 8.  Probing the probes: fitness factors for small molecule tools.

Authors:  Paul Workman; Ian Collins
Journal:  Chem Biol       Date:  2010-06-25

9.  Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors.

Authors:  Lester J Lambert; Celeste Romero; Douglas J Sheffler; Maria Celeridad; Nicholas D P Cosford; Lutz Tautz
Journal:  J Vis Exp       Date:  2020-07-17       Impact factor: 1.355

Review 10.  Discoidin domain receptors in disease.

Authors:  Corina M Borza; Ambra Pozzi
Journal:  Matrix Biol       Date:  2013-12-19       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.